FLLL32 is a potent JAK2/STAT3 inhibitor with IC50 of <5 μM.

HO-3867, an analog of curcumin, is a selective STAT3 inhibitor.

Artesunate is a water-soluble, semi-synthetic derivative of the sesquiterpine lactone artemisinin with anti-malarial, anti-shistosomiasis, antiviral, and potential anti-neoplastic activities.

Niclosamide is an orally bioavailable chlorinated salicylanilide, with anthelmintic and potential antineoplastic activity.

SMI-4a is a potent inhibitor of Pim1, modestly potent to Pim-2, does not significantly inhibit any other serine/threonine- or tyrosine-kinases.

SGI-1776 is a novel ATP competitive inhibitor of Pim1.

Baricitinib is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM in cell-free assays, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2.

Tofacitinib citrate is a novel inhibitor of JAK with IC50 of 1 nM, 20 nM and 112 nM against JAK3, JAK2, and JAK1, respectively.